Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0038454
Disease: Cerebrovascular accident
Cerebrovascular accident
0.100 GeneticVariation group BEFREE Hazard ratios for secondary outcomes, comparing SGLT2 inhibitors with DPP4 inhibitors, were 0.99 (0.85 to 1.17) for myocardial infarction, 0.94 (0.77 to 1.15) for stroke, 0.84 (0.65 to 1.08) for cardiovascular death, and 0.80 (0.69 to 0.92) for any cause death. 31467044 2019
CUI: C0038454
Disease: Cerebrovascular accident
Cerebrovascular accident
0.100 Biomarker group BEFREE Subtype-Dependent Reporting of Stroke With SGLT2 Inhibitors: Implications From a Japanese Pharmacovigilance Study. 31792991 2019
CUI: C0038454
Disease: Cerebrovascular accident
Cerebrovascular accident
0.100 GeneticVariation group BEFREE Electronic databases were searched from inception to 22 October 2018 for randomized controlled trials designed to assess the cardiovascular efficacy of SGLT2 inhibitors or GLP-1RAs with regard to a three-point composite measure of major adverse cardiovascular events (non-fatal stroke, non-fatal myocardial infarction and cardiovascular mortality). 30653708 2019
CUI: C0038454
Disease: Cerebrovascular accident
Cerebrovascular accident
0.100 Biomarker group BEFREE SGLT2 inhibition reduced the risk of cardiovascular death, nonfatal myocardial infarction or nonfatal stroke (RR, 0.81; 95% CI, 0.70-0.94) and heart failure (RR, 0.61; 95% CI, 0.48-0.78), without a clear effect on all-cause mortality (HR, 0.86; 95% CI, 0.73-1.01). 30697905 2019
CUI: C0038454
Disease: Cerebrovascular accident
Cerebrovascular accident
0.100 Biomarker group BEFREE This meta-analysis indicated that SGLT2 inhibitor therapy did not increase stroke incidence, and no significant differences in stroke risk were observed among 3 SGLT2 inhibitors (class effect). 29573118 2018
CUI: C0038454
Disease: Cerebrovascular accident
Cerebrovascular accident
0.100 GeneticVariation group BEFREE To compare the sodium-glucose-cotransporter-2 (SGLT-2) inhibitor dapagliflozin with dipeptidyl peptidase-4 (DPP-4) inhibitors with regard to risk associations with major adverse cardiovascular (CV) events (MACE; non-fatal myocardial infarction, non-fatal stroke or cardiovascular mortality), hospitalization for heart failure (HHF), atrial fibrillation and severe hypoglycaemia in patients with type 2 diabetes (T2D) in a real-world setting. 28771923 2018
CUI: C0038454
Disease: Cerebrovascular accident
Cerebrovascular accident
0.100 GeneticVariation group BEFREE Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2-inhibitors versus other glucose-lowering agents in real-world clinical practice: Results from the CVD-REAL study. 29569378 2018
CUI: C0038454
Disease: Cerebrovascular accident
Cerebrovascular accident
0.100 Biomarker group BEFREE Two network meta-analyses concluded that sodium-glucose cotransporter 2 (SGLT2) inhibitors, mostly due to empagliflozin, decrease all-cause and cardiovascular mortality but increase the risk of nonfatal stroke, genital infection, and volume depletion. 29285488 2017
CUI: C0038454
Disease: Cerebrovascular accident
Cerebrovascular accident
0.100 GeneticVariation group BEFREE As for DPP-4 inhibitors, there was a non-significant trend towards benefit for stroke, whereas a possible increased risk of stroke with SGLT2 inhibitors-and in particular, empagliflozin in the EMPA-REG OUTCOME trial-has been suggested and requires clarification. 28522196 2017
CUI: C0038454
Disease: Cerebrovascular accident
Cerebrovascular accident
0.100 GeneticVariation group BEFREE Stroke paradox with SGLT-2 inhibitors: a play of chance or a viscosity-mediated reality? 27895093 2017